Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Inclusion Criteria: * Age ≥18 and ≤75 years * Urinary albumin:creatinine ratio \> 100 mg/g and ≤ 3500 mg/g in a first morning void urine collection * eGFR ≥ 30 mL/min/1.73m2 * On a stable dose of an ACEi or ARB for at least 4 weeks prior to randomization * Willing to sign informed consent Exclusion Criteria: * Diagnosis of type 1 diabetes * Minimal change disease, unstable rapidly progressing renal disease, and/or renal disease requiring significant immunosuppression, autosomal dominant or autosomal recessive polycystic kidney disease * Hba1c \> 12.5% * Urinary protein excretion \> 3500 mg/day * Heart Failure NYHA Class III or IV * NT-proBNP \> 600 pg/ml * Hemoglobin \<9g/dL * Acute coronary syndrome event within the preceding 6 months * Severe peripheral edema according to investigators opinion * Women of childbearing potential (WOCBP). WOCBP is defined as women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who are not post-menopausal * Pregnancy or breastfeeding * Indication for immunosuppressants according to Investigator's opinion * Active malignancy aside from treated squamous cell or basal cell carcinoma of the skin within the last 5 years. * Use of the co-interventional treatments (outlined in section 5.2) within 6 weeks of screening. * Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolis…